AbstractsNSCLC, metastatic1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
NSCLC, metastatic
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.